Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 31, 2016. The report serves as a notification of transactions involving Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R (1) (a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific insider trading activities and does not contain consolidated financial statements.
Material Changes and Insider Transactions
The following transactions by PDMRs were reported on March 30, 2016:
- C Thomas: Sold 17,000 Ordinary Shares at a price of £14.08 per share.
- P Vallance: Exercised a nil-priced option over 33,406 Ordinary Shares (granted February 28, 2013; vested February 28, 2016). Subsequently sold 24,251 Ordinary Shares at £14.12 per share and 9,155 Ordinary Shares at £14.11 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of director share transactions.
Investor Verification Checklist
- Verify the total number of shares sold by PDMRs against the company's overall share count to assess dilution or selling pressure.
- Confirm the vesting schedule and terms of the Deferred Annual Bonus Plan referenced for P Vallance.
- Review the broader Q1 2016 financial results in the company's Form 20-F or earnings release, as this 6-K does not contain financial performance data.